A Prospective Randomised, Open-Labeled, Trial Comparing Sirolimus-Containing Versus mTOR-Inhibitor-Free Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma.
Phase of Trial: Phase III
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Sirolimus (Primary) ; Immunosuppressants
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms SiLVER
- 27 Sep 2017 Results presented at the 18th Congress of the European Society for Organ Transplantation
- 11 Aug 2010 Trial design was reported in the journal BMC Cancer.
- 03 Jun 2009 Patient enrolment is expected to be complete in early 2009 according an abstract presented at the 2009 ATS meeting. The first interim analysis of the primary endpoint is expected in mid-2009.